Highly bioavailable BCM-95® curcumin extract addresses Alzheimer’s disease beyond the brain
A new study reveals that Kerala-based Arjuna Natural’s CURCUGREEN® (BCM-95®) turmeric extract could potentially help lessen damage from Alzheimer’s disease on organs other than the brain.
With the global population of seniors poised to double by 2050, concern about Alzheimer’s is something of high importance to a third of the world’s population, making its prevention and relief from its symptoms critical issues.
The new study is built on ample previous studies demonstrating the powerful antioxidant, anti-inflammatory, and anti-amyloid properties of curcumin, the most concentrated source being from the turmeric rhizome (Curcuma longa).
The study was conducted on male and female transgenic mice at the Field Neurosciences Institute, Central Michigan University, US, and investigated how the highly bioavailable curcuminoid formulation, CURCUGREEN (BCM-95), can help prevent abnormalities in peripheral organs of sufferers of Alzheimer’s disease.
In the brain, CURCUGREEN (BCM-95) decreased amyloid deposition, pTau, cell loss, and reductions in inflammatory markers. It also reduced enlargement and degeneration of the spleen, inflammation in the kidney, lung damage, and damage to the liver, including enlargement of liver cells and inflammation of the central hepatic vein.
“We are encouraged by this suggestion that curcumin could help against overall damage wrought by this undiscriminating disease,” says Benny Antony, PhD, Joint Managing Director for Arjuna and inventor of CURCUGREEN (BCM-95).